3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
92
Neoplasm Metastasis
10
Neoplasms
9
Breast Diseases
4
Advanced Breast Cancer
3
Recurrence
2
Neoplasms by Site
2
Carcinoma, Renal Cell
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Diseases
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Post Menopausal Women With Early Breast Cancer
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Multiple Endocrine Neoplasia Type 1
1
Mammary Neoplasms, Animal
1
Lymphoma
1
Lung Neoplasms
1
Lung Diseases
1
Lethal Congenital Contracture Syndrome 2
1
Kidney Neoplasms
1
Invasive Early Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Interventions
pembrolizumab
72
Cisplatin
57
Cetuximab
38
Fluorouracil
25
Nivolumab
21
Radiotherapy
20
Carboplatin
19
Paclitaxel
14
Docetaxel
11
Cyclophosphamide
9
Gefitinib
8
fludarabine
7
durvalumab
7
zalutumumab
6
atezolizumab
6
Drug Therapy
6
Bleomycin
6
epacadostat
5
cemiplimab
5
Radiotherapy, Intensity-Modulated
5
Pemetrexed
5
Ipilimumab
5
Gemcitabine
5
Afatinib
5
spartalizumab
4
Standard of Care
4
Radiation
4
Injections
4
Immune Checkpoint Inhibitors
4
Fibroblast Growth Factor 7
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Head and Neck Neoplasms
×
exemestane
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled